Related Experiment Video
Updated: Jan 24, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Challenges in the diagnosis and treatment of secondary acute myeloid leukemia
Gert Ossenkoppele1, Pau Montesinos2
1VU University Medical Center, 2PK Brug 016, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
Abstract:
Secondary AML (sAML), referring to AML arising after prior cytotoxic/radiation/immunosuppressive therapy (tAML) or an antecedent hematologic disorder, now primarily classified as AML with myelodysplasia-related changes (AML-MRC), accounts for 10%-30% of AML cases and is associated with a poor prognosis. sAML has historically been treated with intensive chemotherapy (eg, 7 + 3) or less aggressive regimens (eg, low-dose cytarabine or azacytidine for older/unfit patients); however, outcomes are typically poor, especially for older adults. Recently, CPX-351, a liposomal co-encapsulation of cytarabine and daunorubicin at a synergistic ratio, demonstrated improved front-line outcomes in older patients with high-risk/sAML. CPX-351 has been approved for adults with newly diagnosed tAML or AML-MRC and has an NCCN category 1 recommendation for induction therapy of patients aged >60 years with high-risk/sAML. Other novel therapies may also benefit certain sAML subgroups. Greater clarity around the optimal diagnosis and treatment of sAML patients is needed to improve outcomes in this high-risk subpopulation.
Insights
Secondary AML (sAML), a challenging leukemia subtype, historically shows poor outcomes. Novel therapies like CPX-351 offer improved front-line treatment options for older adults with high-risk sAML.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Secondary acute myeloid leukemia (sAML), including therapy-related AML (tAML) and AML with myelodysplasia-related changes (AML-MRC), represents a significant portion of AML cases (10%-30%).
- sAML is characterized by a poor prognosis, particularly in older adults, with historically suboptimal outcomes using conventional chemotherapy regimens.
- Current treatment strategies for sAML include intensive chemotherapy (e.g., 7+3) or less aggressive options for elderly or unfit patients, but efficacy remains limited.
Purpose of the Study:
- To review the current understanding of secondary AML (sAML) diagnosis and treatment strategies.
- To highlight the efficacy of novel therapeutic approaches, specifically CPX-351, in improving outcomes for patients with high-risk sAML.
- To emphasize the need for optimized diagnostic and therapeutic paradigms for sAML to enhance patient survival and quality of life.
Main Methods:
- Literature review of secondary AML (sAML) classification, treatment history, and emerging therapies.
- Analysis of clinical trial data and treatment guidelines pertaining to sAML management.
- Focus on the role of CPX-351, a liposomal formulation of cytarabine and daunorubicin, in the context of sAML treatment.
Main Results:
- CPX-351 has demonstrated improved front-line outcomes in older patients diagnosed with high-risk sAML.
- CPX-351 is approved for adults with newly diagnosed therapy-related AML (tAML) or AML with myelodysplasia-related changes (AML-MRC).
- The National Comprehensive Cancer Network (NCCN) guidelines recommend CPX-351 as a Category 1 option for induction therapy in patients over 60 with high-risk sAML.
Conclusions:
- CPX-351 represents a significant advancement in the front-line treatment of older adults with high-risk secondary AML.
- While CPX-351 shows promise, further research into optimal diagnostic criteria and novel therapies for specific sAML subgroups is warranted.
- Improving the management of sAML requires a comprehensive approach, integrating diagnostic clarity with effective therapeutic strategies to enhance outcomes in this vulnerable patient population.
Related Concept Videos
Secondary Active Transport
Secondary Active Transport
Secondary Healthcare System
Primary and Secondary Growth in Roots and Shoots
Secondary Distribution
In residential areas, 120/240 V single-phase, three-wire service is commonly used for lighting, outlets, and large appliances. Urban areas with high-density loads...
Secondary Lymphoid Organs
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...

